Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation

Preclinical Data Reported by Roche at 69th Scientific Sessions

SAN FRANCISCO, June 4 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors will be presented in a poster presentation at the 69th Scientific Sessions of the American Diabetes Association June 6, 2009 in New Orleans, LA. The poster will be presented by Roche (SWX: ROG), who licensed its DGAT1 inhibitors exclusively to VIA in December 2008. Dr. Rebecca Taub, Sr. Vice President Research & Development of VIA and a co-author on the poster, managed development of the DGAT1 program at Roche prior to joining the VIA management team.

    The presentation details are as follows:
       Date/Time: Saturday June 6, 2009
                  11:30AM - 1:30PM
                   6:15PM - 7:30PM
       Location: Ernest N. Morial Convention Center
       Session: Insulin Action - Metabolism
       Title: Can DGAT Inhibition Improve Insulin Sensitivity? (Poster 1279-P)

DGAT1 (diacylglycerol acyl transferase-1) is an enzyme that catalyzes triglyceride synthesis and fat storage. Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 inhibitors are believed to be an innovative class of compounds that modify lipid metabolism. In studies of obese animals, DGAT1 inhibitors have been shown to induce weight loss and improve insulin sensitization, glucose tolerance and lipid levels. These observations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine whether any can be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit:

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the September 14, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our failure to timely recruit and enroll patients for the FDG-PET
           clinical trial, as well as any future clinical trial;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of
           VIA-2291 on expected timetables and the outcomes of such clinical
        -- complexities in designing and implementing cardiovascular clinical
           trials using histological examinations, measurement of biomarkers,
           medical imaging and atherosclerotic plaque bioassays;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of the ACS and CEA studies, upon further review and
           analysis, are revised or negated by authorities or by later stage
           clinical trials;
        -- our ability to obtain necessary FDA approvals;
        -- our ability to successfully commercialize VIA-2291;
        -- our ability to identify potential clinical candidates from the
           compounds in DGAT1 and move them into preclinical development;
        -- our ability to obtain and protect our intellectual property related
           to our product candidates;
        -- our potential for future growth and the development of our product
           pipeline, including the THR beta agonist candidate and the other
           compounds licensed from Roche;
        -- our ability to obtain strategic opportunities to partner and
           collaborate with large biotechnology or pharmaceutical companies to
           further develop VIA-2291;
        -- our ability to form and maintain collaborative relationships to
           develop and commercialize our product candidates;
        -- general economic and business conditions; and
        -- the other risks described under Item IA "Risk Factors" in our
           Annual Report on Form 10-K for the fiscal year ended December 31,
           2008 on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
(Date:10/12/2015)... ROSEVILLE, Minn. , Oct. 12, 2015 /PRNewswire/ ... Drug Administration (FDA) has designated its lead Microbiota ... for the treatment of recurrent Clostridium difficile ... gastrointestinal (GI) infection that causes 29,000 deaths in ... clinical stage biotechnology company that was founded to ...
(Date:10/12/2015)... , 12 de octubre de 2015 El ... llegó a un récord en el congreso con su ... de la International Plasma Awareness Week (IPAW), que se ... está patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 2015 offers ... enriched online experience --> ... version for enriched online experience --> ... alternative to print version for enriched online experience ... technical and medical information products and services, announced today ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/7/2015)... October 7, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Washington , former long- term executive at American Express ... --> NXTD ) ("NXT-ID" or the "Company"), a ... market and creator of the Wocket® smart wallet announces ...
Breaking Biology News(10 mins):